Abstract
A nanoaerosol nozzle was designed and the generated aerosol consisting of a diluted dexamethasone solution was measured with Scanning Mobility Particle Sizer (SMPS). The obtained aerosol concentration was fed into the IDEAL lung deposition model for to calculate expected deposition in a human lung. Measurements and calculation clearly show that a substantial fraction reaches the alveolar section of the lungs. Given the generated particle inventory in the nano-size range, the tested nozzle appears to have specic advantages for deposition in deeper pulmonary region over existing “out of the shelf” devices. Considering therapeutic applications, the high share of nano-sized particles make it possible to reduce dosage without compromising the therapeutic effects. While most devices currently in use achieve only about 10 % lung deposition efciency, with the bulk of the aerosolized fraction trapped in the extra-thoracic region. With this novel aerosolizer it is possible to reduce oropharyngeal deposition to about 4,78-5.97 %, leaving 25.6-25.5 % being deposited in the deeper lung, while the remaining fraction being expelled with the exhalation bolus.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
